Mergers & acquisitions
The company’s pipeline was strengthened in the second quarter with three strategic collaborations in immuno-oncology, immuno-neurology, and HIV.
Amgen will gain Teneobio’s proprietary bispecific and multispecific antibody technologies, which have the potential to target multiple diseases across Amgen’s core therapeutic areas.
It’s a busy week for GlaxoSmithKline, although much of it is related to the upcoming demerger of its Consumer Healthcare business. Here’s a look.
Lantern will reacquire the Irofulven program and evaluate its potential for advanced development to treat bladder and prostate cancers.
It’s been a long season of acquisitions for PerkinElmer. Now in its largest purchase ever, the Massachusetts-based company is dropping a massive $5.25 billion in cash and stock to buy biomedical research tool company BioLegend.
The life sciences is always a frenetic sector when it comes to mergers & acquisitions, initial public offerings (IPOs) and Series A announcements (not to mention B and C rounds). But during the second quarter of 2021, these companies were especially busy bees – all positive signs that the industry is still booming coming out of the COVID-19 pandemic.
The Boston-based company merged with Capstar Special Purpose Acquisition Corp. and will begin trading on the New York Stock Exchange under the ticker symbol “GLS.”
BioNTech indicates the acquisition will add production capacity in support of U.S. clinical trials.
Medtech company HeartFlow is heading to the New York Stock Exchange through a merger with special purpose acquisition company, Longview Acquisition Corp. II.
Prenetics, which is a diagnostics and genetics testing company, will merge with Artisan Acquisition, a SPAC company backed by Adrian Cheng, chief executive officer of Hong Kong’s New World Development.
PRESS RELEASES